doi:10.3969/j.issn.1674-490X.2024.05.003

Abstract

Abstract: Objective To observe the effcts of intravitreal of ranibizumab and DEX implant in macular edema secondary to branch retinal vein occlusion(BRVO-ME). Methods 67 cases with BRVO-ME in the Department of Ophthalmology of Baoding No.1 Central Hospital were included from January 2020 to May 2022. According to the different methods of treatment,all patients were divided into ranibizumab group and combined treatment group, 37 cases of 37 eyes in the ranibizumab group and 30 cases of 30 eyes in the combined treatment group. All patients were treated with intravitreal injection of ranibizumab,and the combined treatment group was treated with ranibizumab and 1 week later with 0.7 mg DEX implant. The best corrected visual acuity(BCVA), the central macular thickness(CMT)and the vessel perfusion density(VPD), vessel length density(VLD)were evaluated detected with optical coherence tomography(OCT and OCTA)before and after treatment. Depending on the patient's follow-up, the following situation occurs would stop observing. If intra-retinal/sub-retinal accumulation fluid appeared in the macular area, the BCVA continued to decline, or the CMT≥300 μm, with the increase in CMT. Results There was no significant difference in BCVA and CMT between the combination group and the single drug group at the first diagnosis(P>0.05). After treatment, the BCVA and CMT of the two groups were lower than those before treatment(P<0.05), and the BCVA and CMT of the combination group were lower than those of the single drug group after treatment(P<0.05).While no significant difference was found in VPD and VLD at the central, inner, otuer, full region in the superficial retinal capillary plexus within 6 mm×6 mm of macular area before and after treatment(P>0.05). Conclusion In eyes with BRVO-ME, treatment with an anti-VEGF agent plus DEX implant could provide a predictable duration of effect, as well as significant improvements in BCVA and CMT. However, the early efficacy of the two is similar, and the synergistic effects are not obvious.

Key words: branch retinal vein occlusion, macular edema, dexamethasone, anti-vascular endothelial growth factor, optical coherence tomography angiography

CLC Number:

References

[1] URIAS E A, URIAS G A, MONICKARAJ F, et al. Novel therapeutic targets in diabetic macular edema: beyond VEGF[J]. Vision Res, 2017, 139: 221-227. DOI: 10.1016/j.visres.2017.06.015.
[2] ZHOU J Q, XU L, WANG S, et al. The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study[J]. Ophthalmology, 2013, 120(4): 803-808. DOI: 10.1016/j.ophtha.2012.09.033.
[3] LI J, PAULUS Y M, SHUAI Y L, et al. New developments in the classification, pathogenesis, risk factors, natural history, and treatment of branch retinal vein occlusion[J]. J Ophthalmol, 2017, 2017: 4936924. DOI: 10.1155/2017/4936924.
[4] CUGATI S, WANG J J, ROCHTCHINA E, et al. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study[J]. Arch Ophthalmol, 2006, 124(5): 726-732. DOI: 10.1001/archopht.124.5.726.
[5] KLEIN R, MOSS S E, MEUER S M, et al. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study[J]. Arch Ophthalmol, 2008, 126(4): 513-518. DOI: 10.1001/archopht.126.4.513.
[6] BERGER A R, CRUESS A F, ALTOMARE F, et al. Optimal treatment of retinal vein occlusion: Canadian expert consensus[J]. Ophthalmologica, 2015, 234(1): 6-25. DOI: 10.1159/000381357.
[7] ROGERS S, MCINTOSH R L, CHEUNG N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia[J]. Ophthalmology, 2010, 117(2): 313-319. DOI: 10.1016/j.ophtha.2009.07.017.
[8] 雍红芳,戚卉,吴瑛洁,等.视网膜静脉阻塞继发黄斑水肿发病机制及黄斑水肿影响视功能的研究进展[J].国际眼科杂志, 2019, 19(11): 1888-1891. DOI: 10.3980/j.issn.1672-5123.2019.11.17.
[9] CHATZIRALLI I, THEODOSSIADIS G, PARIKAKIS E, et al. Long-term anatomical and functional outcomes in patients with ischemic central retinal vein occlusion treated with anti-vascular endothelial growth factor agents[J]. Ophthalmic Res, 2017, 58(4): 203-208. DOI: 10.1159/000462976.
[10] CELIK E, DOG ˇAN E, TURKOGLU E B, et al. Serous retinal detachment in patients with macular edema secondary to branch retinal vein occlusion[J]. Arq Bras Oftalmol, 2016, 79(1): 9-11. DOI: 10.5935/0004-2749.20160004.
[11] IIJIMA H. Mechanisms of vision loss in eyes with macular edema associated with retinal vein occlusion[J]. Jpn J Ophthalmol, 2018, 62(3): 265-273. DOI: 10.1007/s10384-018-0586-5.
[12] NOMA H, MINAMOTO A, FUNATSU H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion[J]. Graefe's Arch Clin Exp Ophthalmo, 2006, 244(3): 309-315. DOI: 10.1007/s00417-004-1087-4.
[13] TARALLO V, FALCO S D. The vascular endothelial growth factors and receptors family: up to now the only target for anti-angiogenesis therapy[J]. Int J Biochem Cell Biol, 2015, 64: 185-189. DOI: 10.1016/j.biocel.2015.04.008.
[14] XIA J P, WANG S, ZHANG J S. The anti-inflammatory and anti-oxidative effects of conbercept in treatment of macular edema secondary to retinal vein occlusion[J]. Biochem Biophys Res Commun, 2019, 508(4): 1264-1270. DOI: 10.1016/j.bbrc.2018.12.049.
[15] SIVAPRASAD S, AMOAKU W M, HYKIN P, et al. The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary[J]. Eye, 2015, 29(12): 1633-1638. DOI: 10.1038/eye.2015.164.
[16] PULIDO J S, FLAXEL C J, ADELMAN R A, et al. Retinal vein occlusions preferred practice pattern(^®)guidelines[J]. Ophthalmology, 2016, 123(1): 182-208. DOI: 10.1016/j.ophtha.2015.10.045.
[17] 中华医学会眼科学分会眼底病学组,中国医师协会眼科医师分会眼底病专业委员会.中国视网膜静脉阻塞临床诊疗路径专家共识[J].中华眼底病杂志, 2024, 40(3): 175-185. DOI: 10.3760/cma.j.cn511434-20240201-00056.
[18] 陈露璐,陈有信.2019年《EURETINA视网膜静脉阻塞诊疗指南》解读[J].中华实验眼科杂志, 2020, 38(1): 60-63. DOI: 10.3760/cma.j.issn.2095-0160.2020.01.012.
[19] MYUNG J S, AAKER G D, KISS S. Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant[J]. Clin Ophthalmol, 2010, 4: 1423-1426. DOI: 10.2147/OPTH.S15696.
[20] BOYER D S, YOON Y H, BELFORT R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema[J]. Ophthalmology, 2014, 121(10): 1904-1914. DOI: 10.1016/j.ophtha.2014.04.024.
[21] MISHRA S K, GUPTA A, PATYAL S, et al. Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety[J]. Int J Retina Vitreous, 2018, 4: 13. DOI: 10.1186/s40942-018-0114-2.
[22] BUDZINSKAYA M V, SHELANKOVA A V, PLUKHOVA A, et al. The role of steroids in the management of macular edema from retinal vein occlusion[J]. Ophthalmol Russ, 2019, 16(1): 95-101. DOI: 10.18008/1816-5095-2019-1-95-101.
[23] TAN M H, MCALLISTER I L, GILLIES M E, et al. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion[J]. Am J Ophthalmol, 2014, 157(1): 237-247. DOI: 10.1016/j.ajo.2013.08.013.
[24] SHIRAKATA Y, FUKUDA K, FUJITA T, et al. Pars plana vitrectomy combined with internal limiting membrane peeling for recurrent macular edema due to branch retinal vein occlusion after antivascular endothelial growth factor treatments[J]. Clin Ophthalmol, 2016, 10: 277-283. DOI: 10.2147/OPTH.S85751.
[25] HAHN P. Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye[J]. Clin Ophthalmol, 2014, 8: 2129-2131. DOI: 10.2147/OPTH.S73265.
[26] FLAXEL C J, ADELMAN R A, BAILEY S T, et al. Retinal vein occlusions preferred practice pattern(^®)[J]. Ophthalmology, 2020, 127(2): 288-320. DOI: 10.1016/j.ophtha.2019.09.029.
[27] SINGER M A, JANSEN M E, TYLER L, et al. Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series[J]. Clin Ophthalmol, 2017, 11: 31-38. DOI: 10.2147/OPTH.S119373.
[28] IU L P, ZHAO P, YEUNG I Y, et al. Sequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion[J]. Br J Ophthalmol, 2015, 99(2): 210-214. DOI: 10.1136/bjophthalmol-2014-305661.
[29] AL-KHERSAN H, HARIPRASAD S M, SALEHI-HAD H. Dexamethasone and anti-VEGF combination therapy for the treatment of diabetic macular edema[J]. Ophthalmic Surg Lasers Imaging Retina, 2019, 50(1): 4-7. DOI: 10.3928/23258160-20181212-01.
[30] QIAN T, ZHAO M, XU X. Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: a meta-analysis[J]. J Clin Pharm Ther, 2017, 42(5): 519-529. DOI: 10.1111/jcpt.12551.
[31] MANOUSARIDIS K, PETER S, MENNEL S. Outcome of intravitreal dexamethasone implant for the treatment of ranibizumab-resistant macular edema secondary to retinal vein occlusion[J]. Int Ophthalmol, 2017, 37(1): 47-53. DOI: 10.1007/s10792-016-0226-3.
[32] COSCAS G, AUGUSTIN A, BANDELLO F, et al. Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion[J]. Eur J Ophthalmol, 2014, 24(1): 1-9. DOI: 10.5301/ejo.5000376.
[33] FASSBENDER ADENIRAN J M, JUSUFBEGOVIC D, SCHAAL S. Common and rare ocular side-effects of the dexamethasone implant[J]. Ocul Immunol Inflamm, 2017, 25(6): 834-840. DOI: 10.1080/09273948.2016.1184284.
[34] ZHAO L Q, CHENG J W. A systematic review and meta-analysis of clinical outcomes of intravitreal anti-VEGF agent treatment immediately after cataract surgery for patients with diabetic retinopathy[J]. J Ophthalmol, 2019, 2019: 2648267. DOI: 10.1155/2019/2648267.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(6): 24-28.
[2]	HAO Jianzhang, ZHANG Hu. Prospect of treatment of retinal vein edema combined with macular edema [J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(3): 35-40.